Table 3 Effectiveness and safety
Start <5 weeks (N = 15) | Start >5 months (N = 328) | Total (N = 343) | |
|---|---|---|---|
Involution | |||
complete | 2 (13.3) | 77 (23.9) | 79 (23.4) |
almost complete | 3 (20) | 17 (5.3) | 20 (5.9) |
partial | 10 (66.7) | 218 (67.7) | 228 (67.7) |
absent | 0 | 10 (3.1) | 10 (3) |
Relapse | 1 (6.7) | 39 (12) | 40 (11.8) |
Treatment complications | 1 (6.7) | 52 (15.9) | 53 (15.5) |
irritability | 0 | 17 (5.4) | 17 (5.12) |
sleep disorders | 0 | 22 (6.8) | 22 (6.6) |
cold extremities | 0 | 2 (0.6) | 2 (0.6) |
diarrhoea | 0 | 10 (3.1) | 10 (2.9) |
hypoglicemia | 0 | 1 (0.3) | 1 (0.3) |
hypotension | 0 | 4 (1.3) | 4 (1.2) |